The Jab1 level was found to be a possible biomarker for clinical response to chemotherapy in lung cancer patients and for postoperative relapse in breast cancer patients who received adjuvant chemotherapy (Hou et al., 2017), indicating that Jab1 predicts treatment response in lung cancer and relapse in breast cancer patients. This evidence concerns the gene COPS5 and breast carcinoma.